Daunorubicin HCl
(Synonyms: 盐酸柔红霉素; Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride) 目录号 : GC10354
Antitumor antibiotic used in the treatment of acute myeloid leukemias
Cas No.:23541-50-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Murine melanoma cells (B16F10) and the murine fibroblast NIH/3T3 |
|
Preparation method |
The solubility of this compound in DMSO is >28.2mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
5 to500 μM for 24 h |
|
Applications |
Daunorubicin exerted toxicity against melanoma cells at 15 μM. Daunorubicin caused slight morphology alterations on fibroblast cells and inhibited cell proliferation observed by a decreased cell density when compared with untreated cells. |
| Animal experiment [2]: | |
|
Animal models |
Balb-c mice |
|
Dosage form |
single intraperitoneal , 2.3 to 28.25 μmol/kg |
|
Application |
In Balb-c mice, tumour growth inhibition was slight great in daunorubicin-treated groups at the lower dose (1.8 μmol/kg) while at the higher dose level, tumour growth inhibition under daunorubicin treatment was clearly great (7.5 μmol/kg). All the animals from saline developed metastatic nodes while 80% of daunorubicin-treated groups presented metastatic sites. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Contente TC, Kretzer IF., et al. Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice. J Pharm Pharmacol. 2014 Dec;66(12):1698-709. doi: 10.1111/jphp.12296 |
|
Daunorubicin HCl is an inhibitor of DNA topoisomerase II [1].
Daunorubicin is an anthracycline antibiotic. It is also used as an effective chemotherapeutic agent against tumors especially acute myeloid leukaemia and acute lymphocytic leukaemia. Daunorubicin can affect the metabolism and synthesis of DNA and RNA. In the in vitro assay, daunorubicin inhibits the incorporation of thymidine and uridine into L1210 cells. It also inhibits the incorporation of labeled precursors into the isolated DNA and RNA from incubated cells. When treated with leukemic cells isolated from acute lymphocytic leukemia patients, daunorubicin significantly inhibits the biosynthesis of the DNA and RNA macromolecules [2, 3].
References:
[1] Hande K R. Etoposide: four decades of development of a topoisomerase II inhibitor. European Journal of Cancer, 1998, 34(10): 1514-1521.
[2] Momparler R L, Karon M, Siegel S E, et al. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Research, 1976, 36(8): 2891-2895.
[3] Meriwether W D, Bachur N R. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer research, 1972, 32(6): 1137-1142.
| Cas No. | 23541-50-6 | SDF | |
| 别名 | 盐酸柔红霉素; Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride | ||
| 化学名 | (8S,10S)-8-acetyl-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride | ||
| Canonical SMILES | Cl[H].O=C(C([H])([H])[H])[C@@](C([H])([H])[C@]1([H])O[C@](C([H])([H])[C@]2([H])N([H])[H])([H])O[C@](C([H])([H])[H])([H])[C@@]2([H])O[H])(C([H])([H])C3=C1C(O[H])=C(C(C4=C5C([H])=C([H])C([H])=C4OC([H])([H])[H])=O)C(C5=O)=C3O[H])O[H] | ||
| 分子式 | C27H30ClNO10 | 分子量 | 563.98 |
| 溶解度 | ≥ 80mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7731 mL | 8.8656 mL | 17.7311 mL |
| 5 mM | 0.3546 mL | 1.7731 mL | 3.5462 mL |
| 10 mM | 0.1773 mL | 0.8866 mL | 1.7731 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。